During the past decade, Satucon Oy/Kuopion tyoterveys conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 1 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Satucon Oy/Kuopion tyoterveys" are "Atherosclerotic Cardiovascular Disease" (1 trials), "Coronary Heart Disease (CHD)" (1 trials), "Kidney Disease, Chronic" (1 trials) and "Major Depressive Disorder" (1 trials). Many other conditions were trialed in "Satucon Oy/Kuopion tyoterveys" in a lesser frequency.

Most popular intervention types in "Satucon Oy/Kuopion tyoterveys" are "Drug" (3 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Antidepressant + Placebo" (1 trials), "Antidepressant + SPD489 (Lisdexamfetamine dimesylate )" (1 trials), "BI 690517" (1 trials), "Empagliflozin" (1 trials) and "Evolocumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Satucon Oy/Kuopion tyoterveys" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Satucon Oy/Kuopion tyoterveys". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Satucon Oy/Kuopion tyoterveys, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Satucon Oy/Kuopion tyoterveys, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".